YARDLEY, Pa.--(BUSINESS WIRE)--The first patients have been successfully enrolled in a phase III study involving the intranasal delivery of sumatriptan powder using the OptiNose bi-directional technology. The trial, named TARGET (AssessmenT of Delivery of Drug via A Novel Device to the IntRanasal Cavity for MiGraine PatiEnTs) will evaluate the safety and efficacy of this novel product – specifically assessing the ability to offer rapid pain relief, sustained freedom from pain and other measures. The OptiNose migraine product aims to be the first approved in the U.S. to administer powdered drug particles intranasally.
